Star Combo Pharma Ltd. (S66) AI Stock Analysis

• Market Cap: AU$22.95M
• Dividend Yield: 2.18%
• Average Volume (3M): 7.09K
• Price to Earnings (P/E): 25.8
• Beta (1Y): -0.16
• Revenue Growth: 16.45%
• EPS Growth: 83.33%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Household & Personal Products
• EPS (TTM): <0.01
• Shares Outstanding: 135,002,980
• 10 Day Avg. Volume: 9,495
• 30 Day Avg. Volume: 7,092
• PEG Ratio: N/A
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 6.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Star Combo Pharma Ltd. has moderate financial performance with low leverage but faces profitability and cash flow challenges. Technical indicators suggest positive momentum, tempered by potential overvaluation. The absence of earnings call and corporate events data limits further analysis.

Star Combo Pharma Ltd. Business Overview & Revenue Model

Company Description

Star Combo Pharma Ltd. (S66) is an Australian-based company operating in the health and wellness sector. The company specializes in the manufacturing and distribution of a wide range of pharmaceutical and nutraceutical products. Its core offerings include vitamins, dietary supplements, and skincare products, which are designed to promote health and well-being among consumers. Star Combo Pharma Ltd. focuses on using high-quality ingredients and maintaining rigorous standards to ensure the efficacy and safety of its products.

How the Company Makes Money

Star Combo Pharma Ltd. generates revenue through the sale of its pharmaceutical and nutraceutical products. The company's primary revenue streams include direct sales to consumers, retail partnerships, and wholesale distribution agreements. Additionally, the company leverages international markets by exporting its products to various countries, which contributes significantly to its earnings. Strategic partnerships with retailers and distributors enhance its market reach and drive sales growth. Furthermore, Star Combo Pharma Ltd. invests in research and development to innovate and expand its product portfolio, which in turn supports its revenue generation strategies.

Star Combo Pharma Ltd. Financial Statement Overview

Summary

Star Combo Pharma Ltd. demonstrates moderate financial health with stable revenue growth and low leverage. However, profitability and cash flow conversion remain areas of concern, suggesting potential operational inefficiencies.

Income Statement

Star Combo Pharma Ltd. shows a moderate financial performance with a Gross Profit Margin of 20.9% and a Net Profit Margin of 2.9%. The Revenue Growth Rate is 5.3% annually, indicating a steady increase in sales. However, the EBIT Margin is 2.8%, showcasing limited operational efficiency. While EBITDA Margin stands at 10.7%, there is room for improvement in profitability metrics.

Balance Sheet

The balance sheet reflects a stable financial position, with a Debt-to-Equity Ratio of 0.12, indicating low leverage and financial risk. Return on Equity is 2.2%, showing room for improvement in profitability. The Equity Ratio is high at 77.9%, suggesting a strong reliance on equity financing, which enhances stability.

Cash Flow

The cash flow statement reveals some challenges, with a negative Free Cash Flow Growth Rate of 106.4%, indicating deteriorating cash generation. The Operating Cash Flow to Net Income Ratio is negative, as is the Free Cash Flow to Net Income Ratio, signaling inefficiencies in converting income to cash.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	26.02M	24.70M	22.88M	26.72M	38.84M
Gross Profit	7.41M	7.16M	5.61M	4.61M	5.29M
EBITDA	2.79M	-2.53M	-126.71K	-6.40M	352.23K
Net Income	747.33K	-4.00M	-696.35K	-7.88M	-348.69K
Balance Sheet
Total Assets	42.82M	42.23M	43.44M	43.32M	54.72M
Cash, Cash Equivalents and Short-Term Investments	7.36M	9.49M	10.39M	17.32M	26.60M
Total Debt	4.03M	4.19M	4.12M	3.30M	5.61M
Total Liabilities	9.30M	8.97M	8.04M	7.13M	10.22M
Stockholders Equity	33.32M	33.09M	35.41M	36.19M	44.50M
Cash Flow
Free Cash Flow	-1.76M	-851.83K	-7.21M	-6.93M	-3.80M
Operating Cash Flow	-316.45K	1.88M	87.11K	331.53K	-1.02M
Investing Cash Flow	-136.79K	-3.23M	-3.24M	-7.53M	-3.63M
Financing Cash Flow	-370.93K	-53.44K	-169.08K	-2.08M	26.63M

Star Combo Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:S66, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.15, and above the 200-day MA of 0.14, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.43 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:S66.

Star Combo Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
S66	64 Neutral	AU$22.95M	25.76	2.68%	2.18%	16.45%	83.33%
AGH	53 Neutral	AU$23.85M	―	-218.38%	―	-14.30%	29.69%
LDX	52 Neutral	AU$53.89M	―	-51.49%	―	80.84%	57.59%
Sector *	50 Neutral	AU$2.61B	2.94	-57.47%	2.40%	36.37%	14.48%
ZNO	40 Underperform	AU$11.73M	―	-79.75%	―	-48.53%	55.02%
NC6	40 Underperform	AU$24.41M	―	-1014.79%	―	-70.17%	-41.07%
SKN	30 Underperform	AU$3.15M	―		―	252.94%	81.95%

Star Combo Pharma Ltd. Corporate Events

Star Combo Pharma Secures $5 Million Insurance Settlement Post-Factory Fires

Star Combo Pharma Ltd announced the settlement of insurance claims related to damages from two fires at its factory in 2022, resulting in a $5 million payment. This settlement is expected to provide financial relief and stability, potentially enhancing the company’s operational capabilities and market positioning.